Hims & Hers Health Inc currently trades at $19.39, down from a previous close of $19.50, reflecting a decrease of 0.56%. The company's revenue growth year-over-year stands at an impressive 59%, but the EPS growth has declined by 4.65%, which raises concerns about profitability. With a P/E ratio of 34.43 and a P/B of 13.66, the stock appears overvalued relative to its earnings and book value, especially given the recent downgrades in price targets amidst shifting market dynamics.